1. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD (1992) Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19:663?669
2. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1992) Camptothecin overcomes MDR-1 mediated resistance in human KB carcinoma cells. Cancer Res 51:6039?6044
3. Culine S, DeForni M, Extra JM, Chabot GG, Madelaine I, Heriat P, Bugat R, Marty M, Mathieu-Boué A (1992) Phase I study of the camptothecin analogue CPT-11, using a weekly schedule. Proc Am Soc Clin Oncol 11:110
4. Gandia D, Armand JP, Chabot G (1992) Phase I study of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc Am Assoc Cancer Res 33:260
5. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, Noe DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706?712